• Publications
  • Influence
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
BACKGROUND In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted aExpand
  • 3,173
  • 136
  • PDF
Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab.
PURPOSE A phase II trial was performed to evaluate the safety and efficacy of rituximab, a chimeric anti-CD20 monoclonal antibody, in patients with bulky (> 10-cm lesion) relapsed or refractoryExpand
  • 291
  • 7
Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.
Rituximab and IFN have each demonstrated single-agent activity in patients with low-grade non-Hodgkin's lymphoma (NHL). A single-arm, multicenter, Phase II trial was conducted to assess the safetyExpand
  • 133
  • 5
Colorectal Cancer Screening for Average-Risk North Americans: An Economic Evaluation
An economic analysis of different screening methods for detection of colorectal cancers suggests that in US or Canadian settings, screening with fecal immunochemical testing results in lowerExpand
  • 123
  • 4
  • PDF
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
  • S. Gill, Y. Ko, +11 authors M. Moore
  • Medicine
  • Journal of clinical oncology : official journal…
  • 12 September 2016
Purpose The standard of care for second-line therapy in patients with advanced pancreatic cancer after gemcitabine-based therapy is not clearly defined. The CONKO-003 phase III study reported aExpand
  • 111
  • 3
Cloning and expression in Escherichia coli of a Streptomyces coelicolor A3(2) argCJB gene cluster.
From a partial Sau3AI library of Streptomyces coelicolor A3(2) DNA in pIJ916, two hybrid plasmids pGX1 and pGX2 were isolated that complemented S. coelicolor A3(2) or S. lividans arginine auxotrophs.Expand
  • 26
  • 2
  • PDF
Colorectal liver metastases contract centripetally with a response to chemotherapy
Recently, there has been considerable interest in neoadjuvant chemotherapy for colorectal liver metastases. However, there is little information that defines how much liver should be removed after aExpand
  • 53
  • 1
A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
BackgroundChemotherapy may improve survival in patients undergoing resection of colorectal liver metastases (CLM). Neoadjuvant chemotherapy may help identify patients with occult extrahepatic diseaseExpand
  • 41
  • 1
PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy
4022 Background: There is no current standard of care for APC after 1st line GEM. The CONKO3 study (ASCO 2008) reported a survival benefit with 2nd line oxaliplatin-5FU (OFF), but has not yet been ...
  • 42
  • 1
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma
BackgroundFollowing resection of liver metastases from colorectal cancer, 5-year survivals are reportedly 30 – 39%. It can be assumed that this clinical situation represents systemic disease.Expand
  • 31
  • 1
  • PDF